The Relationship Between Lobbying Spend and Regulatory Outcomes

In 2024, organizations and individuals reported spending $4.3 billion on federal lobbying — a figure that has more than doubled since 2000. The pharmaceutical industry alone spent over $380 million. Oil and gas companies spent $175 million. Tech giants collectively spent over $70 million. These are not acts of charity. The question is not whether lobbying influences policy — the question is how to measure it, and whether the data trail is visible enough to follow.

How Lobbying Disclosure Works

The Lobbying Disclosure Act of 1995 (LDA) requires anyone who is paid to lobby federal officials to register and file quarterly reports. These filings are public and searchable through the Senate's LDA database at lda.senate.gov. Three forms make up the disclosure framework:

LD-1: Registration

Filed when a lobbyist or lobbying firm first registers. It names the client, the lobbying firm (if different), the specific issues to be lobbied on (using standardized issue area codes like "TAX," "ENV," "HCR"), and the specific federal agencies and chambers of Congress to be contacted. The LD-1 is your roadmap — it tells you who hired whom to influence what.

LD-2: Quarterly Activity Report

Filed four times per year, the LD-2 reports income received (for lobbying firms) or expenses incurred (for in-house lobbyists) during the quarter. It lists the specific issues lobbied on, the specific bills or regulations referenced, and the names of lobbyists who made contacts. Income is reported in $10,000 increments for firms and $5,000 increments for organizations. The LD-2 is where the money trail lives.

LD-203: Contribution Report

Filed semi-annually, the LD-203 discloses political contributions made by registered lobbyists to federal candidates, party committees, and PACs. This is the bridge between lobbying activity and campaign finance — it shows which lobbyists are also writing checks to the lawmakers they are lobbying.

Which Industries Spend the Most

Lobbying expenditure is remarkably concentrated. According to data compiled by OpenSecrets from Senate filings, the top five spending sectors consistently are:

1. Pharmaceuticals and Health Products — $380+ million annually. The industry has been the top spender for over two decades, driven by drug pricing debates, FDA approval processes, and Medicare/Medicaid reimbursement rules.
2. Insurance — $180+ million. Health insurance and property/casualty companies lobby heavily on ACA regulations, state mandates, and federal flood insurance.
3. Electronics Manufacturing and Equipment — $170+ million. Semiconductor companies, particularly during the CHIPS Act implementation, have dramatically increased spending.
4. Oil and Gas — $175+ million. Lobbying targets include EPA emissions rules, drilling permits on federal land, LNG export approvals, and pipeline regulations.
5. Business Associations — $160+ million. The U.S. Chamber of Commerce alone typically spends $80-100 million per year, making it the single largest lobbying entity in the country by dollar volume.

Case Studies: From Spending to Outcomes

Pharmaceutical Industry and Drug Pricing

The pharmaceutical industry spent $2.8 billion on lobbying between 2013 and 2023. During this period, multiple legislative proposals to allow Medicare to negotiate drug prices were introduced and defeated. When the Inflation Reduction Act of 2022 finally passed with limited negotiation authority (covering only 10 drugs initially), the final language was significantly narrower than earlier proposals. Senate LD-2 filings show that PhRMA, the industry's primary lobbying group, reported lobbying on every drug pricing bill introduced during this period, consistently listing "issues related to Medicare Part D" and "drug pricing" as lobbying topics.

The correlation is visible: as lobbying spend increased (PhRMA went from $18 million in 2013 to $29 million in 2023), the scope of enacted pricing reforms narrowed. Correlation is not causation — other factors including partisan dynamics and electoral politics played roles — but the timeline is instructive.

Chemical Industry and PFAS Regulation

Between 2019 and 2024, as the EPA moved toward setting enforceable PFAS drinking water standards, the American Chemistry Council and individual chemical manufacturers dramatically increased lobbying on PFAS-related issues. LD-2 filings show ACC lobbying spending rose from $10 million to $14 million annually during this period, with "PFAS," "CERCLA," and "Superfund" appearing as lobbying issues with increasing frequency.

The final PFAS MCLs announced in April 2024 (4 ppt for PFOA and PFOS) were stricter than industry sought, but the compliance timeline extended to 2029 — giving industry five years to implement treatment. The extended timeline closely matched what industry comments on regulations.gov advocated for. Cross-referencing the public comments (docket EPA-HQ-OW-2022-0114) with the lobbying filings shows a coordinated strategy: lobby for delay, comment for delay, get delay.

Cross-Referencing With Regulations.gov

The real analytical power comes from connecting lobbying filings to specific regulatory actions. Here is the methodology:

1. Identify the regulation. Every federal rule goes through a notice-and-comment process documented on regulations.gov. Each rulemaking has a unique docket ID (e.g., EPA-HQ-OAR-2023-0072 for the 2024 power plant emissions rule).
2. Pull lobbying filings. Search the Senate LDA database for LD-2 filings that list the same regulation, bill number, or issue area. Many LD-2 filings now reference specific docket IDs or bill numbers in their "specific lobbying issues" field.
3. Read the public comments. On regulations.gov, download the comments submitted by the same organizations that filed LD-2 reports. Compare what the lobbyists asked for in comments with what appeared in the final rule.
4. Compare proposed vs. final rule. The Federal Register publishes both the proposed rule and the final rule. The preamble of the final rule explains why the agency changed (or did not change) specific provisions. Look for provisions that shifted between proposed and final in ways that align with industry lobbying positions.
5. Check the timeline. Plot lobbying expenditures by quarter against the rulemaking timeline (ANPRM, NPRM, comment period, final rule). Spikes in lobbying spend that coincide with the comment period or the OMB review period are particularly telling.

Deep Seer's RegulatoryDeltaEngine automates much of this cross-referencing, tracking changes between proposed and final rules and correlating them with lobbying filings and public comments from the same entities.

Statistical Approaches to Measuring Influence

Researchers studying lobbying effectiveness use several methodological approaches:

Regression Analysis

The most common approach regresses regulatory outcomes (binary: regulation passed/weakened/blocked) against lobbying expenditure, controlling for confounders like party control of Congress, agency leadership, public opinion, and media coverage. A widely cited 2009 study by Frank Baumgartner and colleagues at UNC-Chapel Hill found that the side spending more on lobbying won roughly 60% of the time on major policy issues — statistically significant but far from deterministic.

Difference-in-Differences

Compare industries that increased lobbying spend around a specific regulatory event to similar industries that did not. If the industries that spent more on lobbying saw more favorable regulatory outcomes, the difference in outcomes provides an estimate of lobbying's causal effect. This approach controls for broader economic and political trends that affect all industries equally.

Event Study Design

Examine what happens to stock prices of companies in a lobbied sector when a favorable regulation is announced. If markets believe lobbying was effective, stock prices should rise for firms in the sector, particularly for the heaviest lobbying spenders. Alexander, Scholz, and Mazza (2009) found that firms lobbying on the American Jobs Creation Act of 2004 saw returns exceeding 22,000% on their lobbying investment in the form of tax savings.

Network Analysis

Map the connections between lobbyists (named on LD-2 filings), the officials they contact, the committees those officials sit on, and the regulations those committees oversee. The density of connections between a lobbying client and a specific committee often predicts the committee's disposition on issues the client cares about. Former staffers who become lobbyists — the "revolving door" — are particularly valuable nodes in these networks.

The Limits of What Data Can Show

Lobbying disclosure data has significant blind spots. Grassroots lobbying (campaigns that mobilize constituents to contact their representatives) is not covered by the LDA. Strategic communications — hiring PR firms to shape media coverage of a regulatory issue — is not considered lobbying. And the $4.3 billion reported under the LDA is widely understood to be a fraction of total influence spending when you include think tank funding, academic research sponsorship, and shadow lobbying by consultants who structure their activities to fall below the registration threshold.

What the data can show is a pattern: when an industry spends heavily on lobbying around a specific regulation, and the final regulation differs from the proposed regulation in ways that align with the industry's stated preferences, the inference — while not proof of causation — is difficult to dismiss. The paper trail exists. It is public. And the tools to analyze it are increasingly accessible to anyone willing to do the work.